Mayo Clinic and Orion to Validate Breast Cancer Biomarkers | GenomeWeb
This correction clarifies that the alliance is to validate, not identify, breast cancer biomarkers.
 
NEW YORK (GenomeWeb News) — Orion Genomics will work with researchers at the Mayo Clinic to validate the company’s breast cancer screening technology in a clinical environment.
 
Orion will use its epigenetic biomarker-based technology with physicians at Mayo Clinic’s Department of Laboratory Medicine and Pathology to analyze cross-reactivity in more than a dozen types of breast cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.